CNTA Relative Valuation
CNTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNTA is overvalued; if below, it's undervalued.
Historical Valuation
Centessa Pharmaceuticals PLC (CNTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.41. The fair price of Centessa Pharmaceuticals PLC (CNTA) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：15.69
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
5.52
P/B
Median3y
3.10
Median5y
3.55
-7.75
FCF Yield
Median3y
-26.92
Median5y
-23.54
Competitors Valuation Multiple
The average P/S ratio for CNTA's competitors is 16.91, providing a benchmark for relative valuation. Centessa Pharmaceuticals PLC Corp (CNTA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Centessa Pharmaceuticals PLC (CNTA) currently overvalued or undervalued?
What is Centessa Pharmaceuticals PLC (CNTA) fair value?
How does CNTA's valuation metrics compare to the industry average?
What is the current P/B ratio for Centessa Pharmaceuticals PLC (CNTA) as of Jul 19 2025?
What is the current FCF Yield for Centessa Pharmaceuticals PLC (CNTA) as of Jul 19 2025?
What is the current Forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA) as of Jul 19 2025?